 Connection
Edward Gardner to HIV Protease Inhibitors
This is a "connection" page, showing publications Edward Gardner has written about HIV Protease Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.595 |
|
|
|
-
Hawkins KL, Montague BT, Rowan SE, Beum R, McLees MP, Johnson S, Gardner EM. Boosted darunavir and dolutegravir dual therapy among a cohort of highly treatment-experienced individuals. Antivir Ther. 2019; 24(7):513-519.
Score: 0.604
-
Gardner EM, Melendez AG, Astiz M, Bray K. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):34-9.
Score: 0.366
-
Gardner EM, Hullsiek KH, Telzak EE, Sharma S, Peng G, Burman WJ, MacArthur RD, Chesney M, Friedland G, Mannheimer SB. Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial. AIDS. 2010 Jan 28; 24(3):395-403.
Score: 0.325
-
Gardner EM, Sharma S, Peng G, Hullsiek KH, Burman WJ, Macarthur RD, Chesney M, Telzak EE, Friedland G, Mannheimer SB. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS. 2008 Jan 02; 22(1):75-82.
Score: 0.282
-
Mannheimer SB, Wold N, Gardner EM, Telzak EE, Huppler Hullsiek K, Chesney M, Wu AW, MacArthur RD, Matts J, Friedland G. Mild-to-moderate symptoms during the first year of antiretroviral therapy worsen quality of life in HIV-infected individuals. Clin Infect Dis. 2008 Mar 15; 46(6):941-5.
Score: 0.018
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|